Available online on 15.05.2026 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Open Access Full Text Article

Review Article

Advanced Drug Delivery Approaches for Antidiabetic Agents: Strategies to Enhance Bioavailability, Efficacy, and Patient Compliance

H G Srusti[1*], K Darshini[2], K V Poorvika[3], Bramhotri Rout[4]

[1,2,3] *Department of Pharmacology, Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka, India - 572103.*

[4] *Department of Pharmacology, The Oxford College of Pharmacy, Bangalore, Karnataka, India - 560068*

Article Info:

Article History:

Received 23 Feb 2026
Reviewed 11 April 2026
Accepted 04 May 2026
Published 15 May 2026

Cite this article as:

Srusti HG, Darshini K, Poorvika KV, Rout B, Advanced Drug Delivery Approaches for Antidiabetic Agents: Strategies to Enhance Bioavailability, Efficacy, and Patient Compliance, Journal of Drug Delivery and Therapeutics. 2026; 16(5):182-191 *DOI: https://dx.doi.org/10.22270/jddt.v16i5.7739*

For Correspondence:

H G Srusti, Department of Pharmacology, Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka, India - 572103;

Abstract

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to impaired insulin secretion, insulin action, or both. The global burden of diabetes is increasing rapidly, posing significant challenges to healthcare systems worldwide. Although several antidiabetic agents are available, their clinical effectiveness is often limited by poor bioavailability, rapid degradation, frequent dosing requirements, and low patient adherence.

Advanced drug delivery systems have emerged as a promising strategy to overcome these limitations by improving pharmacokinetics, enhancing drug stability, and enabling controlled or targeted release. Various novel systems such as nanoparticles, lipid-based carriers, polymeric systems, transdermal systems, and glucose-responsive drug delivery systems have shown significant improvements in therapeutic outcomes.

This review provides a comprehensive discussion on advanced drug delivery approaches for antidiabetic agents, focusing on strategies to enhance bioavailability, therapeutic efficacy, and patient compliance, along with challenges and future perspectives in clinical translation.

Keywords: Antidiabetic delivery, Drug delivery, Bioavailability enhancement, Controlled release, Glucose-responsive, Patient compliance.

Introduction

Diabetes mellitus is one of the most prevalent chronic diseases globally, affecting hundreds of millions of people. It is characterized by elevated blood glucose levels resulting from defects in insulin secretion, insulin resistance, or both[1]. The disease is broadly classified into Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus[2].

Management of diabetes requires lifelong pharmacological intervention. Commonly used antidiabetic agents include insulin, metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Despite the availability of these drugs, achieving optimal glycemic control remains challenging due to pharmacokinetic limitations and patient-related factors[3].

Conventional drug delivery systems often suffer from poor solubility, enzymatic degradation, limited absorption, and short biological half-life. For instance, insulin, a peptide hormone, cannot be administered orally due to degradation in the gastrointestinal tract. Similarly, many oral hypoglycemic drugs exhibit variable absorption and significant side effects[4].

These limitations lead to poor patient compliance, especially in long-term therapy where multiple daily doses or injections are required. Therefore, there is a strong need for advanced drug delivery systems that can improve drug performance and patient outcomes.

Rationale for Advanced Drug Delivery in Diabetes

The main goal of advanced drug delivery systems in diabetes management is to overcome the limitations of conventional therapies. These systems are designed to:

- Improve drug solubility and stability
- Enhance oral bioavailability
- Provide controlled and sustained drug release
- Enable targeted drug delivery

- Reduce dosing frequency
- Improve patient compliance
- Minimize side effects and toxicity

Advanced systems also aim to mimic physiological insulin secretion, thereby maintaining glucose homeostasis more effectively.



Figure 1: Overview of Advanced drug delivery approaches for antidiabetic agents

Limitations of Conventional Antidiabetic Therapy

Despite being widely used, conventional antidiabetic therapies have several limitations that reduce their effectiveness[4].

a. Poor Oral Bioavailability

Many antidiabetic drugs suffer from low solubility and permeability, leading to inconsistent absorption. Drugs like glibenclamide and repaglinide show variable bioavailability due to poor dissolution in gastrointestinal fluids[5].

b. Enzymatic Degradation

Peptide-based drugs such as insulin and GLP-1 analogs are rapidly degraded by proteolytic enzymes in the gastrointestinal tract, making oral delivery ineffective[6].

c. Short Half-Life

Several antidiabetic drugs have a short biological half-life, requiring frequent administration. This increases treatment burden and reduces adherence[7].

d. First-Pass Metabolism

Orally administered drugs undergo hepatic first-pass metabolism, significantly reducing systemic drug availability[8].

e. Poor Patient Compliance

Injectable insulin therapy is associated with pain, inconvenience, and psychological resistance, leading to poor compliance among patients[9].

f. Side Effects

Conventional therapies are associated with side effects such as hypoglycemia, weight gain, and gastrointestinal disturbances[10].

Need for Advanced Drug Delivery Systems

To overcome these challenges, advanced drug delivery systems have been developed. These systems aim to improve therapeutic outcomes by enhancing drug absorption, controlling release profiles, and enabling targeted delivery. Nanotechnology, polymer science, and lipid-based systems have revolutionized drug delivery in diabetes management. These technologies allow drugs to be delivered in a more efficient and patient-friendly manner. These innovations represent a major shift from conventional dosage forms to smart and controlled delivery systems.

Table 1: Conventional vs Advanced Drug Delivery Systems in Antidiabetic Therapy

Parameter	Conventional Drug Delivery	Advanced Drug Delivery Systems
Drug release profile	Immediate / uncontrolled	Controlled / sustained / stimuli-responsive
Bioavailability	Low to moderate	High and improved
Dosing frequency	Multiple daily doses	Once daily / weekly / programmable
Patient compliance	Poor (especially injections)	High (non-invasive options available)
Targeting ability	Non-specific systemic distribution	Site-specific / targeted delivery
Stability of drugs	Low (especially peptides)	High protection via encapsulation
Examples	Oral metformin, regular insulin	Nanoparticles, liposomes, microneedles

Nanoparticle-Based Drug Delivery Systems

Nanoparticle-based drug delivery systems represent one of the most extensively explored strategies for improving the therapeutic performance of antidiabetic agents. Nanoparticles typically range from 1-1000 nm and provide unique advantages due to their small size, large surface area, and ability to modify drug release kinetics[11]. These systems enhance solubility, improve stability, and facilitate targeted drug delivery to specific tissues[12].

Polymeric nanoparticles such as those made from PLGA, chitosan, and alginate are widely used in diabetes therapy. These carriers can encapsulate both hydrophilic and hydrophobic drugs, protecting them from enzymatic degradation. For example, insulin-loaded chitosan nanoparticles improve intestinal absorption due to their mucoadhesive properties and ability to transiently open tight junctions in the intestinal epithelium[13].

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are also important lipid-based nanocarriers that improve drug stability and controlled release. These systems are particularly useful for poorly water-soluble drugs such as glibenclamide, where they enhance dissolution rate and oral bioavailability[14].

Despite their advantages, nanoparticle systems face challenges such as physical instability, aggregation, large-scale manufacturing difficulties, and regulatory concerns regarding long-term safety[15].

Table 2: Nanoparticle-Based Drug Delivery Systems for Antidiabetic Drugs

System Type	Polymer/Lipid Used	Drug Loaded	Mechanism of Action	Advantages	Limitations
Polymeric nanoparticles	PLGA, chitosan	Insulin, metformin	Mucoadhesion, sustained release	Improved absorption, protection from enzymes	Scale-up difficulty
Solid lipid nanoparticles (SLNs)	Lipid matrix (glyceryl behenate)	Glibenclamide	Lipid-based controlled release	High stability, biocompatibility	Drug expulsion risk
Nanostructured lipid carriers (NLCs)	Solid + liquid lipids	Repaglinide	Enhanced dissolution	High loading capacity	Stability issues
Nanoemulsions	Surfactant + oil phase	Pioglitazone	Improved solubilization	Rapid absorption	Surfactant toxicity risk

Lipid-Based Drug Delivery Systems

Lipid-based drug delivery systems have gained significant attention due to their ability to improve the solubility and absorption of poorly water-soluble antidiabetic drugs[16]. These systems include liposomes, niosomes, and self-emulsifying drug delivery systems (SEDDS).

Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and lipophilic drugs. They protect drugs from enzymatic degradation and enhance systemic circulation time. In diabetes therapy, liposomal insulin formulations have shown improved stability and controlled release profiles[17].

Niosomes are non-ionic surfactant-based vesicles that offer improved stability compared to liposomes. They enhance drug permeability and provide sustained drug release, making them suitable for oral and transdermal delivery[18].

Cubosomes are lipid-based nanocarriers composed of monoolein and stabilizers like Poloxamer 407, forming a bicontinuous cubic structure. They can encapsulate hydrophilic, lipophilic, and amphiphilic drugs, providing controlled and sustained release. In diabetes management, cubosomes improve drug stability, enhance bioavailability, and prolong therapeutic action. However, their application is limited by complex formulation and scalability challenges[19].

Self-emulsifying drug delivery systems (SEDDS) are isotropic mixtures of oils, surfactants, and co-solvents that spontaneously form fine oil-in-water emulsions in the gastrointestinal tract. This enhances drug solubilization and promotes lymphatic absorption, thereby bypassing hepatic first-pass metabolism. Drugs such as repaglinide and glibenclamide have shown improved bioavailability using SEDDS formulations[20].



Figure 2: self-emulsifying drug delivery system

However, issues such as formulation stability, potential drug leakage, and scale-up challenges remain limitations for clinical translation.

Table 3: Lipid-Based Drug Delivery Systems in Diabetes Management

System	Composition	Drug Type	Key Mechanism	Therapeutic Benefit	Challenges
Liposomes	Phospholipids + cholesterol	Insulin, peptides	Vesicular encapsulation	Protection from degradation	Leakage, instability
Niosomes	Non-ionic surfactants	Glipizide	Bilayer vesicle formation	Improved stability over liposomes	Limited scalability
Cubosomes	Monoolein (glyceryl monooleate) + stabilizers (e.g., Poloxamer 407)	Insulin, metformin, peptides	Bicontinuous cubic phase structure enabling controlled release	Sustained release, high drug loading, improved stability	Complex formulation, high production cost, scalability issues
SEDDS	Oils, surfactants, co-solvents	Glibenclamide	Spontaneous emulsification	Enhanced oral bioavailability	Formulation optimization
Self-micro emulsifying systems (SMEDDS)	Similar to SEDDS (nano-size droplets)	Repaglinide	Lymphatic absorption	Bypasses first-pass metabolism	High surfactant content

Polymeric Drug Delivery Systems

Polymeric drug delivery systems are widely used in antidiabetic therapy due to their versatility, biocompatibility, and ability to provide controlled drug release. These systems include hydrogels, micelles, and dendrimers[21].

Hydrogels are three-dimensional hydrophilic polymer networks capable of absorbing large amounts of water. They are particularly useful in glucose-responsive insulin delivery systems. These smart hydrogels can release insulin in response to elevated glucose levels by

incorporating glucose-sensitive enzymes such as glucose oxidase[22].

Polymeric micelles are nanosized structures formed by the self-assembly of amphiphilic polymers. They are particularly effective in improving the solubility of hydrophobic antidiabetic drugs and enabling sustained release[23].

Dendrimers are highly branched, monodisperse macromolecules that allow precise control over drug loading and release. Their surface functional groups can be modified for targeted drug delivery applications[24].

Overall, polymeric systems provide excellent control over drug release kinetics and are highly promising for next-generation diabetes therapy.

Transdermal Drug Delivery Systems

Transdermal drug delivery systems provide a non-invasive alternative to oral and injectable routes of administration. These systems deliver drugs through the skin into systemic circulation, bypassing gastrointestinal degradation and hepatic first-pass metabolism.

Microneedle-based systems are among the most promising transdermal technologies for insulin delivery. These microscopic needles painlessly penetrate the stratum corneum and deliver drugs directly into the dermal layer, improving patient comfort and compliance[25].



Figure 3: Microneedle-Based Delivery of Insulin

Transdermal patches are also widely studied for delivering antidiabetic drugs in a controlled manner. These systems maintain steady plasma drug levels and reduce dosing frequency. However, the main challenge lies in the limited permeability of the skin barrier, which restricts the delivery of large molecules such as insulin[26].

Oral Controlled Release Drug Delivery Systems

Oral controlled release systems are designed to maintain a constant drug concentration in plasma over an extended period of time. These systems reduce dosing frequency and improve therapeutic efficiency[27].



Figure 4: Oral Controlled Release System (Matrix Tablets)

Matrix tablets are commonly used controlled release systems in which the drug is embedded in a polymer matrix that slowly releases the drug over time. Osmotic pump systems provide highly controlled and predictable drug release by utilizing osmotic pressure as the driving force[28].

Floating drug delivery systems are designed to remain in the gastric environment for extended periods, enhancing drug absorption in the upper gastrointestinal tract. Metformin extended-release formulations are widely used to reduce gastrointestinal side effects and improve patient adherence[29].

Glucose-Responsive (Smart) Drug Delivery Systems

Glucose-responsive drug delivery systems represent a major advancement in diabetes treatment. These systems are designed to automatically release insulin in response to changes in blood glucose levels, thereby mimicking the natural function of pancreatic beta cells.

These systems typically use glucose-sensitive materials such as glucose oxidase, phenylboronic acid derivatives, or Concanavalin A. When blood glucose levels rise, these systems undergo structural changes that trigger insulin release[30].

The major advantage of these systems is their ability to prevent hypoglycemia by releasing insulin only when needed. This self-regulated mechanism significantly improves glycemic control and patient safety. However, challenges such as long-term stability, immune response, and clinical scalability still need to be addressed.

Table 4: Polymeric and Stimuli-Responsive Drug Delivery Systems

System	Stimulus Type	Drug Example	Mechanism	Advantages	Limitations
Hydrogels	Glucose-responsive	Insulin	Enzyme-triggered swelling	Mimics pancreas	Stability issues
Micelles	pH/temperature	Metformin	Self-assembly delivery	Improves solubility	Rapid disassembly
Dendrimers	Surface modification	GLP-1 analogs	Controlled release	High precision delivery	Complex synthesis
Smart polymers	Glucose oxidase-based	Insulin	Glucose-triggered release	Self-regulating system	Limited clinical data

Table 5: Transdermal and Alternative Drug Delivery Systems

System	Route	Drug	Mechanism	Advantages	Limitations
Transdermal patch	Skin	Insulin, metformin	Diffusion across dermis	Non-invasive, sustained release	Limited permeability
Microneedles	Skin microchannels	Insulin	Painless penetration	High compliance	Fabrication complexity
Nasal delivery	Nasal mucosa	Insulin	Rapid absorption	Fast onset	Mucociliary clearance
Pulmonary delivery	Lung alveoli	Inhalable insulin	Large surface absorption	Rapid systemic action	Limited acceptance

Strategies to Enhance Bioavailability of Antidiabetic Agents

Improving bioavailability is a central goal in the development of advanced drug delivery systems for antidiabetic agents. Many drugs, particularly oral hypoglycemics and peptide-based molecules, suffer from poor absorption, enzymatic degradation, and low permeability. Several formulation strategies have been developed to overcome these barriers[31].

One of the most effective approaches is particle size reduction through nanotechnology, which significantly increases the surface area of the drug, thereby enhancing dissolution rate and absorption. Nanosizing of drugs such as glibenclamide and repaglinide has shown improved oral bioavailability due to enhanced gastrointestinal uptake[32].

Another important strategy is the use of lipid-based formulations, which improve solubility of lipophilic drugs and promote lymphatic absorption. These systems bypass hepatic first-pass metabolism, resulting in higher systemic availability of the drug.

Permeation enhancers such as bile salts, surfactants, and fatty acids are also used to temporarily alter membrane permeability, allowing better drug transport across intestinal epithelial barriers.

The prodrug approach involves chemically modifying the drug molecule to improve its physicochemical properties. Once absorbed, the prodrug is converted into the active form, thereby improving bioavailability[33].

Additionally, mucoadhesive drug delivery systems increase the residence time of the drug in the gastrointestinal tract, leading to prolonged absorption and improved therapeutic levels[34].

Table 6: Strategies to Enhance Bioavailability of Antidiabetic Drugs

Strategy	Mechanism	Example Drug	Outcome	Limitation
Nanonization	Particle size reduction	Glibenclamide	Increased dissolution rate	Cost-intensive
Lipid carriers	Lymphatic transport	Repaglinide	Improved oral absorption	Stability issues
Prodrug approach	Chemical modification	Metformin derivatives	Enhanced permeability	Metabolic variability
Permeation enhancers	Membrane modulation	Insulin (oral systems)	Increased GI absorption	Mucosal irritation
Mucoadhesive systems	Prolonged GI retention	Insulin nanoparticles	Extended absorption time	Limited patient variability

Strategies to Enhance Therapeutic Efficacy

Therapeutic efficacy in diabetes management depends on maintaining optimal drug concentration at the target site for a sufficient duration. Advanced drug delivery systems enhance efficacy by providing controlled and sustained drug release[35].

Targeted drug delivery systems, such as nanoparticles and liposomes, deliver drugs directly to specific tissues, reducing off-target effects and improving therapeutic response. This is particularly important in insulin delivery, where precise glucose control is required.

Controlled release formulations ensure a steady release of drug over time, minimizing fluctuations in plasma concentration. This helps in maintaining stable blood glucose levels and reduces the risk of hypoglycemia and hyperglycemia[36].

Combination drug delivery systems, where two or more antidiabetic agents are co-encapsulated, have also shown improved synergistic effects. For example, combining metformin with GLP-1 receptor agonists in a single delivery system can improve glycemic control more effectively than monotherapy[37].

Overall, these strategies enhance pharmacodynamic performance while minimising adverse effects.

Strategies to Improve Patient Compliance

Patient compliance is one of the most critical factors in the successful management of diabetes. Poor adherence to therapy often results in uncontrolled blood glucose levels and long-term complications[38].

Advanced drug delivery systems improve compliance by reducing dosing frequency through sustained and controlled release formulations. Once-daily or weekly formulations significantly reduce the burden on patients compared to multiple daily dosing[39].

Non-invasive drug delivery systems such as oral, transdermal, inhalable, and buccal routes eliminate the need for injections, thereby improving patient comfort and acceptance. Technologies such as transdermal patches and microneedle systems provide painless drug administration, which is particularly beneficial for

insulin therapy. In addition, smart insulin delivery systems that respond to glucose levels reduce the need for frequent monitoring and dose adjustments, simplifying diabetes management. User-friendly devices such as insulin pens and wearable infusion pumps also contribute to improved adherence by making drug administration easier and more convenient[40].

Clinical Applications and Recent Advances

Recent clinical advancements in drug delivery for diabetes have led to the development of several innovative products and technologies.

Inhalable insulin formulations, such as dry powder inhalers, offer rapid absorption through the pulmonary route and provide an alternative to injectable insulin. Although not widely adopted, they represent a significant step toward non-invasive insulin delivery. Continuous subcutaneous insulin infusion (CSII) systems, commonly known as insulin pumps, allow precise and programmable insulin delivery, improving glycemic control in Type 1 diabetes patients[41].

Artificial pancreas systems integrate continuous glucose monitoring with automated insulin delivery, creating a closed-loop system that closely mimics physiological insulin regulation.

Recent research also focuses on 3D-printed drug delivery systems, which allow personalized dosing and release profiles tailored to individual patient needs[42].

Comparative Summary of Advanced Strategies

Advanced drug delivery systems can be broadly compared based on their impact on key therapeutic parameters:

Nanoparticle-based systems primarily improve bioavailability and targeting efficiency. Lipid-based systems enhance solubility and absorption. Polymeric systems provide controlled and stimuli-responsive release. Transdermal systems improve patient compliance by eliminating injections. Glucose-responsive systems offer intelligent, self-regulated insulin delivery[43].

Each system has unique advantages and limitations, and their selection depends on the drug properties and therapeutic requirements[44].

Table 7: Emerging Technologies in Antidiabetic Drug Delivery

Technology	Principle	Application	Advantage	Current Status
Artificial pancreas	Closed-loop insulin control	Type 1 diabetes	Automated glucose control	Clinical use
3D printed dosage forms	Layer-by-layer fabrication	Personalized medicine	Custom dosing	Experimental
AI-based systems	Predictive glucose control	Insulin dosing optimization	Precision therapy	Emerging
Wearable biosensors	Continuous glucose monitoring	Real-time feedback	Improved compliance	Commercial
Nanorobotics (future concept)	Targeted cellular delivery	Insulin delivery	Ultra-precision therapy	Research stage

Conclusion

Advanced drug delivery systems have significantly transformed the therapeutic landscape of diabetes management by addressing the major limitations associated with conventional antidiabetic therapies. Challenges such as poor bioavailability, enzymatic degradation, short half-life, and low patient compliance have been effectively targeted through innovative approaches including nanoparticles, lipid-based carriers, polymeric systems, transdermal technologies, and glucose-responsive delivery platforms.

These advanced systems enhance drug solubility, protect labile molecules like insulin from degradation, and enable controlled, sustained, and targeted drug release. As a result, they improve pharmacokinetic and pharmacodynamic profiles, leading to better glycemic control and reduced side effects. Technologies such as microneedles, insulin pumps, and smart glucose-responsive systems further contribute to improved patient adherence by minimizing pain, reducing dosing frequency, and simplifying disease management.

Moreover, emerging innovations such as artificial pancreas systems, AI-integrated drug delivery, and 3D-printed personalized medicines represent the future of precision diabetes therapy. These advancements aim to closely mimic physiological insulin regulation and offer individualized treatment strategies.

However, despite promising outcomes, several challenges remain, including large-scale manufacturing, long-term safety concerns, regulatory hurdles, and cost-effectiveness. Addressing these issues is essential for successful clinical translation and widespread adoption.

In conclusion, advanced drug delivery approaches hold immense potential to revolutionize diabetes treatment by improving bioavailability, therapeutic efficacy, and patient compliance. Continued research, technological integration, and clinical validation will be crucial in bringing these innovative systems from laboratory research to real-world clinical practice.

Conflict of Interest: The authors declare no potential conflict of interest concerning the contents, authorship, and/or publication of this article.

Author Contributions: All authors have equal contributions in the preparation of the manuscript and compilation.

Source of Support: Nil

Funding: The authors declared that this study has received no financial support.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data supporting this paper are available in the cited references.

Ethical approval: Not applicable.

References

1. Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus. Handbook of clinical neurology. 2014 Jan 1;126:211-22. https://doi.org/10.1016/B978-0-444-53480-4.00015-1
2. Shabnam A, Safia B. Review on pharmacological therapies for management of gestational diabetes. Int J Pharm Sci Dev Res. 2023 Sept 2;9(1):012-018. https://doi.org/10.17352/ijpsdr.000047
3. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Apr 19;164(11):740-751. https://doi.org/10.7326/M15-2650 PMid:27088241
4. Kanzarkar M, Pathak PP, Vaidya M, Brumlik C, Choudhury A. Oral insulin-delivery system for diabetes mellitus. Pharm Pat Anal. 2015 Jan 1;4(1):29-36. https://doi.org/10.4155/ppa.14.53 PMid:25565158
5. Kokil GR, Veedu RN, Ramm GA, Prins JB, Parekh HS. Type 2 diabetes mellitus: limitations of conventional therapies and intervention with nucleic acid-based therapeutics. Chemical Reviews. 2015 Jun 10;115(11):4719-43. https://doi.org/10.1021/cr5002832 PMid:25918949
6. Wong CY, Martinez J, Dass CR. Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities. Journal of Pharmacy and Pharmacology. 2016 Sep;68(9):1093-108. https://doi.org/10.1111/jphp.12607 PMid:27364922
7. Jiang X, Zhang P, Li S, Tan X, Hu Z, Deng B, Wang K, Li C, Sullivan MA, Li E, Gilbert RG. Molecular-size dependence of glycogen enzymatic degradation and its importance for diabetes. European Polymer Journal. 2016 Sep 1;82:175-80. https://doi.org/10.1016/j.eurpolymj.2016.07.017
8. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient preference and adherence. 2016 Jul 22:1299-307. https://doi.org/10.2147/PPA.S106821 PMid:27524885 PMCid:PMC4966497
9. Taha NM, Abd El-Azeaz MA, Abd El-Razik BG. Factors affecting compliance of diabetic patients toward therapeutic management. Diabetes. 2025;5(6).
10. Grunberger G. Should side effects influence the selection of antidiabetic therapies in type 2 diabetes. Current Diabetes Reports. 2017 Apr;17(4):21. https://doi.org/10.1007/s11892-017-0853-8 PMid:28293908
11. Zaric BL, Obradovic M, Sudar-Milovanovic E, Nedeljkovic J, Lazic V, Isenovic ER. Drug delivery systems for diabetes treatment. Current pharmaceutical design. 2019 Jan 1;25(2):166-73. https://doi.org/10.2174/1381612825666190306153838 PMid:30848184
12. Sharma G, Sharma AR, Nam JS, Doss GP, Lee SS, Chakraborty C. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. Journal of nanobiotechnology. 2015 Oct 24;13(1):74. https://doi.org/10.1186/s12951-015-0136-y PMid:26498972 PMCid:PMC4619439
13. Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zakharova LY, Silva AM, Durazzo A, Lucarini M, Izzo AA, Santini A. Nanoparticle delivery systems in the treatment of diabetes complications. Molecules. 2019 Nov 20;24(23):4209. https://doi.org/10.3390/molecules24234209 PMid:31756981 PMCid:PMC6930606
14. Samavati SS, Kashanian S, Derakhshankhah H, Rabiei M. Nanoparticle application in diabetes drug delivery. Journal of Nanoparticle Research. 2022 Sep;24(9):178. https://doi.org/10.1007/s11051-022-05547-8
15. Yang F, Xue J, Wang G, Diao Q. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in pharmacology. 2022 Sep 12;13:999404. https://doi.org/10.3389/fphar.2022.999404 PMid:36172197 PMCid:PMC9512262
16. Kandregula B, Narisepalli S, Chitkara D, Mittal A. Exploration of lipid-based nanocarriers as drug delivery systems in diabetic foot ulcer. Molecular Pharmaceutics. 2022 Apr 28;19(7):1977-98. https://doi.org/10.1021/acs.molpharmaceut.1c00970 PMid:35481377
17. Hu M, Gou T, Chen Y, Xu M, Chen R, Zhou T, Liu J, Peng C, Ye Q. A novel drug delivery system: hyodeoxycholic acid-modified metformin liposomes for type 2 diabetes treatment. Molecules. 2023 Mar 8;28(6):2471. https://doi.org/10.3390/molecules28062471 PMid:36985444 PMCid:PMC10055618
18. Teaima MH, Gebril MI, Abd Allah FI, El-Nabarawi MA. Niosomes versus proniosomes as promising drug delivery systems in treatment of diabetes mellitus. Int J App Pharm. 2022;14(5):32-40. https://doi.org/10.22159/ijap.2022v14i5.44039
19. Uppar AL, Patil CC, Namannavar S, Deshmane PA. Formulation and evaluation of Caffeine-Loaded Cubosomes hydrogel for topical delivery. Journal of Drug Delivery and Therapeutics. 2026 Apr 15;16(4):39-47. Available from: https://doi.org/10.22270/jddt.v16i4.7666 https://doi.org/10.22270/jddt.v16i4.7666
20. Rashid M, Wani TU, Mishra N, Sofi HS, Ashraf R, Sheikh FA. Development and characterization of drug-loaded self-solid nano-emulsified drug delivery system for treatment of diabetes. Material Science Research India. 2018 Apr 20;15(1):01-11. https://doi.org/10.13005/msri/150101
21. Zaric BL, Obradovic M, Sudar-Milovanovic E, Nedeljkovic J, Lazic V, Isenovic ER. Drug delivery systems for diabetes treatment. Current pharmaceutical design. 2019 Jan 1;25(2):166-73. https://doi.org/10.2174/1381612825666190306153838 PMid:30848184
22. Fuchs S, Ernst AU, Wang LH, Shariati K, Wang X, Liu Q, Ma M. Hydrogels in emerging technologies for type 1 diabetes. Chemical reviews. 2020 Dec 28;121(18):11458-526. https://doi.org/10.1021/acs.chemrev.0c01062 PMid:33370102
23. Kaur J, Gulati M, Zacconi F, Dureja H, Loebenberg R, Ansari MS, AlOmeir O, Alam A, Chellappan DK, Gupta G, Jha NK. Biomedical Applications of polymeric micelles in the treatment of diabetes mellitus: Current success and future approaches. Expert Opinion on Drug Delivery. 2022 Jul 3;19(7):771-93.

https://doi.org/10.1080/17425247.2022.2087629 PMid:35695697
24. Mishra V, Yadav N, Saraogi GK, Tambuwala MM, Giri N. Dendrimer based nanoarchitectures in diabetes management: An overview. Current Pharmaceutical Design. 2019 Jun 1;25(23):2569-83. https://doi.org/10.2174/1381612825666190716125332 PMid:31333099
25. Li WX, Zhang XP, Chen BZ, Fei WM, Cui Y, Zhang CY, Guo XD. An update on microneedle-based systems for diabetes. Drug Delivery and Translational Research. 2022 Oct;12(10):2275-86. https://doi.org/10.1007/s13346-021-01113-2 PMid:35112330
26. Mishra MK, Ray D, Barik BB. Microcapsules and transdermal patch: a comparative approach for improved delivery of antidiabetic drug. Aaps Pharmscitech. 2009 Sep;10(3):928-34. https://doi.org/10.1208/s12249-009-9289-z PMid:19629706 PMCid:PMC2802161
27. Ige P, Swami B, Patil T, Pradhan J, Patil P, Nerkar P, Surana SJ. Design and development of sustained release swelling matrix tablets of glipizide for type II diabetes mellitus. Farmacia. 2013 Sep 1;61:883-901.
28. Sharma N, Agarwal D, Gupta MK, Khinchi M. A comprehensive review on floating drug delivery system. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2011 Apr;2(2):428-41.
29. Liu J, Yi X, Zhang J, Yao Y, Panichayupakaranant P, Chen H. Recent advances in the drugs and glucose-responsive drug delivery systems for the treatment of diabetes: a systematic review. Pharmaceutics. 2024 Oct 20;16(10):1343. https://doi.org/10.3390/pharmaceutics16101343 PMid:39458671 PMCid:PMC11511183
30. Zhang J, Xu J, Lim J, Nolan JK, Lee H, Lee CH. Wearable glucose monitoring and implantable drug delivery systems for diabetes management. Advanced Healthcare Materials. 2021 Sep;10(17):2100194. https://doi.org/10.1002/adhm.202100194 PMid:33930258
31. Perin PC, Fornengo P. New oral antidiabetic agents. Internal and Emergency Medicine. 2011 Oct 1;6:135. https://doi.org/10.1007/s11739-011-0677-5 PMid:22009626
32. Dholakia J, Prabhakar B, Shende P. Strategies for the delivery of antidiabetic drugs via intranasal route. International Journal of Pharmaceutics. 2021 Oct 25;608:121068. https://doi.org/10.1016/j.ijpharm.2021.121068 PMid:34481011
33. Tan PK, Kuppusamy UR, Chua KH, Arumugam B. Emerging strategies to improve the stability and bioavailability of insulin: An update on formulations and delivery approaches. Current Drug Delivery. 2023 Oct 1;20(8):1141-62. https://doi.org/10.2174/1567201820666221102094433 PMid:36330644
34. J Meneses M, M Silva B, Sousa M, Sá R, F Oliveira P, G Alves M. Antidiabetic drugs: mechanisms of action and potential outcomes on cellular metabolism. Current pharmaceutical design. 2015 Aug 1;21(25):3606-20. https://doi.org/10.2174/1381612821666150710145753 PMid:26166608
35. Sivakumar PM, Prabhawathi V, Zarrabi A, Akthar S, Prabhakar PK. Current trends in the therapeutic strategies for diabetes management. Current Medicinal Chemistry. 2021 Jul 1;28(23):4616-37. https://doi.org/10.2174/0929867328666210218183914 PMid:33602069
36. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes care. 2009 Apr 1;32(4):531-40. https://doi.org/10.2337/dc08-2064 PMid:19336638 PMCid:PMC2660456
37. Tiwari P. Recent trends in therapeutic approaches for diabetes management: a comprehensive update. Journal of diabetes research. 2015;2015(1):340838. https://doi.org/10.1155/2015/340838 PMid:26273667 PMCid:PMC4530263
38. Turabian JL. Strategies and methods to improve compliance in special patient groups and with specific health problems. Arch Community Med Public Health. 2020 Jun 22;6(1):104-9. https://doi.org/10.17352/2455-5479.000088
39. Abinaya SK, Aanandhi VM. An improvement in patient compliance in diabetes mellitus. Research Journal of Pharmacy and Technology. 2018 Feb 1;11(2):587-92. https://doi.org/10.5958/0974-360X.2018.00108.7
40. Vallis M, Jin S, Klimek-Abercrombie A, Bunko A, Kukaswadia A, Neish CS, Ivers NM. Understanding strategies to improve medication adherence among persons with type 2 diabetes: A scoping review. Diabetic Medicine. 2023 Jan;40(1):e14941. https://doi.org/10.1111/dme.14941 PMid:35996880
41. Kwon SY, Moon JS. Advances in continuous glucose monitoring: clinical applications. Endocrinology and Metabolism. 2025 Apr 8;40(2):161-73. https://doi.org/10.3803/EnM.2025.2370 PMid:40195726 PMCid:PMC12061739
42. Ansari MA, Chauhan W, Shoaib S, Alyahya SA, Ali M, Ashraf H, Alomary MN, Al-Suhaimi EA. Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions. International Journal of Obesity. 2023 Dec;47(12):1179-99. https://doi.org/10.1038/s41366-023-01369-3 PMid:37696926
43. Lundgrin EL, Kelly CA, Bellini N, Lewis C, Rafi E, Hatipoglu B. Diabetes technology trends: a review of the latest innovations. The Journal of Clinical Endocrinology & Metabolism. 2025 Apr;110(Supplement_2):S165-74. https://doi.org/10.1210/clinem/dgaf034 PMid:39998918
44. Williams DM, Jones H, Stephens JW. Personalized type 2 diabetes management: an update on recent advances and recommendations. Diabetes, metabolic syndrome and obesity: targets and therapy. 2022 Jan 1:281-95. https://doi.org/10.2147/DMSO.S331654 PMid:35153495 PMCid:PMC8824792